H
HighLife
Development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation
About HighLife
HighLife SAS is a Paris medtech company developing a transfemoral transcatheter mitral valve replacement (TMVR) system for symptomatic moderate-severe or severe mitral regurgitation in patients unsuitable for surgery or edge-to-edge repair. Founded in 2010 and also operating in Irvine, California, its valve-in-ring concept (annuloplasty-style Sub Annular Implant plus valve prosthesis) mimics surgical practice and aims for durable, anatomically versatile replacement. In 2026 HighLife received CE Mark for its TMVR system (January) and for the next-generation Clarity Valve (July), enabling a limited European market release alongside a US pivotal study. In September 2026 HighLife closed a $90+ million (€80 million) financing round co-led by Andera Partners, Sofinnova Partners, Supernova Invest and Mérieux Equity Partners, with the European Investment Bank, BNP Paribas Développement, Capricorn Partners, Critical Path Ventures, Pro Benefis Familiae, SPRIM Global Investments, a global strategic and existing investors USVP, Sectoral and VI Partners, to accelerate European commercial expansion and US clinical development. Sources: GlobeNewswire / Business Insider 22 Sep 2026; highlifemedical.com.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Morzine, France
- Employees
- 95
- Open positions
- None listed
- Dealroom signal
- 89.2/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Developer Tools, Cardiology and cardiovascular, Patient Care, Hard Tech, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES CEquity / VC | Dec 2020 | $0 | — | Undisclosed | — |
| SERIES B✓Equity / VC | Jan 2019 | $35M | $141M | Sectoral Asset Management · Sofinnova Partners · U.S. Venture Partners · Andera Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for HighLife is 1.9K monthly website visits, up 58.3% over the last three months. HighLife's team grew 30.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Sofinnova Partners
LivaNova- GBGeorg Börtlein
Sectoral Asset Management
U.S. Venture Partners
Andera Partners
Other known investors1 additional known investor
VI Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HighLife on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HighLife’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.